TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24071751

Group type: EXPERIMENTAL
Intervention: Simulation-based education program (3-hour lecture, 3-hour clinical training, 2-hour simulation)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (3-hour lecture only)
Number of subjects: 49
Study: 20507285

Group type: EXPERIMENTAL
Intervention: B-mode ultrasound system with a linear transducer of 7.5 MHz for evaluation of flow-mediated vasodilation in brachial artery (FMV)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Plasma cholesterol
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Duration of diabetes
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Glycemia
Number of subjects: 171
Study: 18677147

Group type: EXPERIMENTAL
Intervention: Evidence-based medicine practices in menopausal management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized clinical trials (RCTs)
Number of subjects: 0
Study: 15776267

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) injections (Hylan G-F 20), 3 intra-articular injections at one-week intervals
Number of subjects: 105

Group type: COMPARATOR
Intervention: Progressive knee exercises (PE) for 6 weeks
Number of subjects: 105

Group type: COMPARATOR
Intervention: Progressive knee exercises (PE)
Number of subjects: 105
Study: 14639556

Group type: EXPERIMENTAL
Intervention: Aquatic exercise (n=10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: On-land exercise (n=10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 30
Study: 12012627

Group type: EXPERIMENTAL
Intervention: E2 + TMG (estradiol + trimegestone)
Number of subjects: 634

Group type: COMPARATOR
Intervention: EV + NG (estradiol valerate + norgestrel)
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: E2 + TMG
Number of subjects: 634

Group type: COMPARATOR
Intervention: EV + NG
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 634
Study: 10734527

Group type: EXPERIMENTAL
Intervention: Electro-convulsive therapy (ECT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 70
Study: 8724322

Group type: EXPERIMENTAL
Intervention: IUDs
Number of subjects: 0
Study: 1955002

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) (250 micrograms.puff‐1), beginning with 1,000 micrograms daily
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 124
Study: 6122339

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 4084668

Group type: EXPERIMENTAL
Intervention: Morning dose of cibenzoline (8.00 am)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Evening dose of cibenzoline (10.00 pm)
Number of subjects: 8
Study: 30449071

Group type: EXPERIMENTAL
Intervention: Local treatment: surgery radiotherapy (55%)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Exclusive surgery (28%)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Radiotherapy (17%)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Postchemotherapy surgery without postoperative radiotherapy (PORT)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Initial surgery without previous chemotherapy, with PORT
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 47
Study: 27050045

Group type: EXPERIMENTAL
Intervention: Yoga Therapy (YT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard Medical Care (SMC)
Number of subjects: 69
Study: 25697379

Group type: EXPERIMENTAL
Intervention: Yoga program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Exercise program
Number of subjects: 20
Study: 22905811

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/day
Number of subjects: 422

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study: 20600013

Group type: COMPARATOR
Intervention: Peg‐IFNα‐2a 180 μg every week
Number of subjects: 1331

Group type: EXPERIMENTAL
Intervention: albIFN 900 μg every 2 weeks
Number of subjects: 1331

Group type: EXPERIMENTAL
Intervention: albIFN 1200 μg every 2 weeks
Number of subjects: 1331
Study: 18198165

Group type: EXPERIMENTAL
Intervention: Comprehensive Motion Apparatus (CMA) treatment, thrice-weekly 30-min treatments for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group, single-blind control of equal duration and intensity
Number of subjects: 50
Study: 16429317

Group type: EXPERIMENTAL
Intervention: pioglitazone (45 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: glibenclamide (5 mg/day)
Number of subjects: 22
Study: 14738027

Group type: EXPERIMENTAL
Intervention: CA-125 level > or = 43.1 U/mL in women with symptoms of imminent abortion
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: CA-125 level threshold of 66.5 U/mL for patients with bleeding of > or = 3 days
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Serum beta-hCG levels
Number of subjects: 200

Group type: COMPARATOR
Intervention: CA-125 levels in groups II and III
Number of subjects: 200
Study: 10941601

Group type: EXPERIMENTAL
Intervention: Achillea drops (hydroalcoholic extract), 15-20 drops twice daily for more than 6 months
Number of subjects: 120
Study: 9196140

Group type: EXPERIMENTAL
Intervention: Acyclovir (800 mg by mouth daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 1588260

Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg orally daily)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 3709630

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ), 10 mg kg‐1
Number of subjects: 12
Study: 30965384

Group type: EXPERIMENTAL
Intervention: Psychological intervention (76-page psychoeducational resource and three telephone-based sessions with a psychologist)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 164
Study: 30555717

Group type: EXPERIMENTAL
Intervention: Lumbar muscle stabilisation exercises (LMSE)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Back endurance-resistance exercises (BERE)
Number of subjects: 32
Study: 27655507

Group type: EXPERIMENTAL
Intervention: (18)F‐FDG PET‐CT
Number of subjects: 70

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 70
Study: 25093998

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg twice daily) and Simvastatin (40 mg twice daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg twice daily), Simvastatin (40 mg twice daily), and NaRLA (600 mg three times daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 22445597

Group type: EXPERIMENTAL
Intervention: Clopidogrel with PPI
Number of subjects: 302

Group type: COMPARATOR
Intervention: Ticlopidine with PPI
Number of subjects: 302
Study: 20360503

Group type: EXPERIMENTAL
Intervention: Ergometer cycling
Number of subjects: 362

Group type: COMPARATOR
Intervention: Control (no ergometer cycling)
Number of subjects: 362
Study: 18683819

Group type: EXPERIMENTAL
Intervention: 100 microg Se/day as high-Se-yeast
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: 200 microg Se/day as high-Se-yeast
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: 300 microg Se/day as high-Se-yeast
Number of subjects: 501

Group type: COMPARATOR
Intervention: Placebo-yeast
Number of subjects: 501
Study: 16179660

Group type: EXPERIMENTAL
Intervention: Testosterone (0.5 mg sublingually)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 12660937

Group type: EXPERIMENTAL
Intervention: Zinc and placebo (Z group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin A and zinc (AZ group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin A and placebo (A group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both placebos (P group)
Number of subjects: 0
Study: 10759624

Group type: EXPERIMENTAL
Intervention: nabumetone (1500-2000 mg/day)
Number of subjects: 694

Group type: COMPARATOR
Intervention: diclofenac SR (100 mg/day)
Number of subjects: 694

Group type: COMPARATOR
Intervention: piroxicam (20-30 mg/day)
Number of subjects: 694
Study: 8703252

Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 3407

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 3407

Group type: EXPERIMENTAL
Intervention: Induction as part of expectant management
Number of subjects: 3407

Group type: EXPERIMENTAL
Intervention: Spontaneous or induced labor as part of induction policy
Number of subjects: 3407
Study: 1385087

Group type: EXPERIMENTAL
Intervention: Oddball paradigm with 1 deviant (P = 0.20)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oddball paradigm with 2 deviants (each with a probability of 0.10)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular alternation of tones of 2 pitches (P = 0.20)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random presentation of tones of 5 different pitches (P = 0.20)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Count conditions (where infrequent events were designated as targets)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Count conditions
Number of subjects: 0
Study: 6693322

Group type: EXPERIMENTAL
Intervention: Inspiratory loads (I)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Expiratory loads (E)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Inspiratory and Expiratory loads (I and E)
Number of subjects: 6
Study: 28825422

Group type: EXPERIMENTAL
Intervention: MDMA (1 mg/kg) during encoding
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MDMA (1 mg/kg) during retrieval
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28636405

Group type: EXPERIMENTAL
Intervention: Home respiratory polygraphy
Number of subjects: 430

Group type: COMPARATOR
Intervention: Polysomnography
Number of subjects: 430
Study: 25394762

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 µg/kg) for 10 min preoperatively
Number of subjects: 37

Group type: COMPARATOR
Intervention: 0.9% normal saline (control)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (0.9% normal saline)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group
Number of subjects: 37
Study: 22260216

Group type: EXPERIMENTAL
Intervention: Aprepitant 200 mg (p.o. given as a 2-hour pre-treatment)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oxycodone (20 and 40 mg/70 kg oral; 15 and 30 mg/70 kg intranasal)
Number of subjects: 8
Study: 21228691

Group type: EXPERIMENTAL
Intervention: Instrumented spinal fusion
Number of subjects: 51

Group type: COMPARATOR
Intervention: Uninstrumented spinal fusion
Number of subjects: 51
Study: 18838046

Group type: COMPARATOR
Intervention: Epidural neostigmine (0.3 mg) with 10 mL of 0.75% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Systemic dexmedetomidine (loading dose of 1 mug kg‐1 over 10 min followed by 0.4 mug kg‐1 h‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Co-administered neostigmine and dexmedetomidine
Number of subjects: 60
Study: 16809238

Group type: EXPERIMENTAL
Intervention: Telephone calls promoting treatment adherence (initial call and biweekly calls)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Control group received only initial and final telephone calls
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Both groups received three packages of salmeterol/fluticasone for 3 months
Number of subjects: 271
Study: 12939779

Group type: EXPERIMENTAL
Intervention: Logistic regression models with baseline adjustment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Logistic regression models without baseline adjustment
Number of subjects: 0
Study: 11037047

Group type: EXPERIMENTAL
Intervention: Moving images
Number of subjects: 0

Group type: COMPARATOR
Intervention: Still images
Number of subjects: 0
Study: 8896531

Group type: EXPERIMENTAL
Intervention: DTPa vaccine
Number of subjects: 0
Study: 1636474

Group type: EXPERIMENTAL
Intervention: High KCAL preload
Number of subjects: 0

Group type: COMPARATOR
Intervention: No preload
Number of subjects: 0
Study: 3975490

Group type: EXPERIMENTAL
Intervention: Zaditen
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30817782

Group type: EXPERIMENTAL
Intervention: Non-talking rule (patients requested not to talk)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Talking condition (patients allowed to talk)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Non-talking rule
Number of subjects: 263

Group type: COMPARATOR
Intervention: Talking condition
Number of subjects: 263
Study: 28937313

Group type: EXPERIMENTAL
Intervention: MiECC with cell-saver
Number of subjects: 0

Group type: COMPARATOR
Intervention: MiECC with direct re-transfusion of shed blood (Control)
Number of subjects: 0
Study: 27638294

Group type: EXPERIMENTAL
Intervention: Local anesthetic (0.25% bupivacaine)
Number of subjects: 74
Study: 24965167

Group type: COMPARATOR
Intervention: Losartan (LS) 50 mg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Combination of Losartan (LS) 50 mg and Hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 102
Study: 22008090

Group type: EXPERIMENTAL
Intervention: With calcium channel blocker (CCB) (n = 1807)
Number of subjects: 3031

Group type: EXPERIMENTAL
Intervention: With CCB plus valsartan (n = 773)
Number of subjects: 3031

Group type: EXPERIMENTAL
Intervention: Without CCB plus valsartan (n = 744)
Number of subjects: 3031
Study: 19506172

Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex gum (4 mg, unflavored) for 4 weeks before and 8 weeks after the target quit date.
Number of subjects: 314

Group type: COMPARATOR
Intervention: Usual care with nicotine gum for 8 weeks after the quit date.
Number of subjects: 314
Study: 17474951

Group type: EXPERIMENTAL
Intervention: Cerebral State Index (CSI)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: A‐line ARX (AAI)
Number of subjects: 20
Study: 14709943

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) at high doses
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study: 11463009

Group type: EXPERIMENTAL
Intervention: Prophylactic bilateral total mastectomy
Number of subjects: 139

Group type: COMPARATOR
Intervention: Regular surveillance (Control)
Number of subjects: 139
Study: 9640570

Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) applied during trabeculectomy
Number of subjects: 59

Group type: COMPARATOR
Intervention: No Mitomycin-C (MMC) applied during trabeculectomy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) applied during triple procedure
Number of subjects: 59

Group type: COMPARATOR
Intervention: No Mitomycin-C (MMC) applied during triple procedure
Number of subjects: 59
Study: 8956477

Group type: EXPERIMENTAL
Intervention: 280 mg GLY-GLN per kg body weight/day for 4 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 450 mg GLY-GLN per kg body weight/day for 4 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 570 mg GLY-GLN per kg body weight/day for 4 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Total parenteral nutrition without GLY-GLN supplementation
Number of subjects: 9
Study: 1903813

Group type: EXPERIMENTAL
Intervention: Phenothrin lotion
Number of subjects: 101

Group type: COMPARATOR
Intervention: Malathion lotion
Number of subjects: 101

Group type: COMPARATOR
Intervention: Carbaryl lotion
Number of subjects: 101
Study: 6998600

Group type: EXPERIMENTAL
Intervention: Proxicromil, administered orally before antigen challenge, dosage not specified, duration of action studied for at least 12 hours.
Number of subjects: 10
Study: 30602342

Group type: EXPERIMENTAL
Intervention: RCEA ACX (°)
Number of subjects: 325
Study: 31103124

Group type: EXPERIMENTAL
Intervention: Resistance training (RG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sophrology (SG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 60
Study: 27743470

Group type: EXPERIMENTAL
Intervention: TEAM rehabilitation program
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 53
Study: 23179140

Group type: EXPERIMENTAL
Intervention: Single group education session on APAP therapy
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (no education session)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Group education session
Number of subjects: 146
Study: 20443014

Group type: EXPERIMENTAL
Intervention: Angeliq (drospirenone 2 mg and estradiol 1 mg)
Number of subjects: 32
Study: 19264047

Group type: EXPERIMENTAL
Intervention: Recurrent pressure ulcers (PrUs)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 24
Study: 16895884

Group type: EXPERIMENTAL
Intervention: 1000 microg vitamin B-12
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: 1000 microg vitamin B-12 + 400 microg folic acid
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study: 14756978

Group type: EXPERIMENTAL
Intervention: Weekly meeting (WM) group
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Correspondent (CR) group
Number of subjects: 98

Group type: COMPARATOR
Intervention: Usual care (UC) group
Number of subjects: 98
Study: 11716665

Group type: EXPERIMENTAL
Intervention: Physician recommendation of hormone replacement therapy (HRT)
Number of subjects: 581
Study: 9056061

Group type: EXPERIMENTAL
Intervention: Activated charcoal (80 g total dose, administered starting 4 h after sodium valproate)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (no activated charcoal)
Number of subjects: 7
Study: 8419816

Group type: EXPERIMENTAL
Intervention: Amoxicillin (750 mg three times daily) plus Metronidazole (500 mg three times daily) for 12 days, along with Ranitidine (300 mg each night) for 6 or 10 weeks.
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo for 12 days, along with Ranitidine (300 mg each night) for 6 or 10 weeks.
Number of subjects: 104
Study: 3465793

Group type: EXPERIMENTAL
Intervention: Dental insurance plans requiring no cost sharing
Number of subjects: 264

Group type: COMPARATOR
Intervention: Cost-sharing dental insurance plans
Number of subjects: 264
Study: 31490311

Group type: EXPERIMENTAL
Intervention: 30% garlic ointment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Vaseline
Number of subjects: 17
Study: 29735088

Group type: EXPERIMENTAL
Intervention: Red beet juice
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Crunchy slices
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both products
Number of subjects: 12
Study: 27382257

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 64

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 64
Study: 24824629

Group type: EXPERIMENTAL
Intervention: 450 mg lithium carbonate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1350 mg lithium carbonate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 23121768

Group type: EXPERIMENTAL
Intervention: Ethanol locks (70% ethanol, once per week)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Heparin locks (thrice per week)
Number of subjects: 49
Study: 20130408

Group type: EXPERIMENTAL
Intervention: Crushed buprenorphine tablets
Number of subjects: 16

Group type: COMPARATOR
Intervention: Whole buprenorphine tablets
Number of subjects: 16

Group type: COMPARATOR
Intervention: Crushed placebo tablets
Number of subjects: 16

Group type: COMPARATOR
Intervention: Whole placebo tablets
Number of subjects: 16
Study: 18816321

Group type: EXPERIMENTAL
Intervention: Decision Aid (DA) booklet
Number of subjects: 31
Study: 16114153

Group type: EXPERIMENTAL
Intervention: Oral 30% dextrose (2 ml)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sterile water (2 ml)
Number of subjects: 52
Study: 11799504

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 15

Group type: COMPARATOR
Intervention: Waking state
Number of subjects: 15
Study: 10067266

Group type: COMPARATOR
Intervention: SK (Streptokinase) group (3750 IU/hour)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: SK-Plg (Streptokinase + exogenous lys-plasminogen 7.5 mg)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: SK-Plg group
Number of subjects: 88
Study: 8638984

Group type: EXPERIMENTAL
Intervention: EHRZ (Ethambutol, HRZ)
Number of subjects: 907

Group type: COMPARATOR
Intervention: SHRZ (Streptomycin, HRZ)
Number of subjects: 907
Study: 1672921

Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 30

Group type: COMPARATOR
Intervention: Temazepam
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7069582

Group type: EXPERIMENTAL
Intervention: Solution (1 g of ascorbic acid)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Tablet (1 g of ascorbic acid)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Timed-release capsule (1 g of ascorbic acid)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Intravenous dose of ascorbic acid
Number of subjects: 4
Study: 30503849

Group type: EXPERIMENTAL
Intervention: Progressive Circuit Resistance Training (CRT) for 8 weeks (3 times/week, 65-85% of 1 repetition maximum)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Progressive Circuit Resistance Training (CRT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 28069563

Group type: EXPERIMENTAL
Intervention: Brief cognitive-behavioural therapy (CBT) plus treatment as usual (TAU)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 220
Study: 25481862

Group type: EXPERIMENTAL
Intervention: Regular chocolate chip cookie
Number of subjects: 300

Group type: COMPARATOR
Intervention: Sugar-free chocolate chip cookie
Number of subjects: 300
Study: 23806610

Group type: EXPERIMENTAL
Intervention: Pilates exercise program for 6 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional exercise program for 6 months
Number of subjects: 50
Study: 20646862

Group type: EXPERIMENTAL
Intervention: High-precision radiotherapy (three-dimensional conformal radiotherapy or intensity-modulated radiation therapy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-precision radiotherapy
Number of subjects: 60
Study: 19770437

Group type: EXPERIMENTAL
Intervention: Tanned children
Number of subjects: 131

Group type: COMPARATOR
Intervention: Minimally tanned children
Number of subjects: 131

Group type: COMPARATOR
Intervention: Darker-skinned white children
Number of subjects: 131